Trial Profile
Randomized Phase II Study of Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Nov 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Urelumab (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 13 Nov 2023 Planned primary completion date changed from 31 Jul 2023 to 31 Jul 2024.
- 26 Jan 2023 Planned primary completion date changed from 1 Dec 2021 to 31 Jul 2023.
- 26 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.